RxDoctor Payments Data

Karen Going

Adult Health · Hudson Falls, NYNPI 1588962369

Payments from drug & device makers

$2,496in general payments, 2019–2025

Across 110 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$482
  • Novo Nordisk$417
  • AstraZeneca$310
  • Lilly USA, LLC$218
  • E.r. Squibb & Sons, L.L.C.$199
  • Bayer$162
  • plus $708 from 10 others

What the payments were for

  • Food & beverage$2,496100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,496 in reported general payments places this provider in the 80th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$26,088
Medicare patients
106
Services billed
536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$84,438
JardianceEmpagliflozin53$64,105
EliquisApixaban45$56,573
TrulicityDulaglutide52$54,764
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$53,534
JanuviaSitagliptin Phosphate18$18,831
FarxigaDapagliflozin Propanediol25$18,703
EntrestoSacubitril/Valsartan12$17,378
MounjaroTirzepatide11$14,354
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$13,042
XareltoRivaroxaban11$11,105
Breo ElliptaFluticasone/Vilanterol26$9,175
OxycontinOxycodone Hcl17$7,737
SymbicortBudesonide/Formoterol Fumarate20$5,296
Rosuvastatin Calcium383$5,040

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$417$84,43876 claims
Lilly USA, LLCTrulicity, Mounjaro$218$69,11863 claims
Boehringer IngelheimJardiance$70$64,10553 claims
GSKTrelegy Ellipta, Breo Ellipta$482$62,710107 claims
PfizerEliquis$143$56,57345 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$310$37,04159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,828 adult health providers in New York.

Other adult health in Hudson Falls

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →